Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DVAX one month down. Stock moves from 2$ to 12$ now trading at 5.40$ good pipline vaccines stock
End Sept beginning October covid 19 news expected
DVAX is a buy now. End September beginning October covid19 news expected
DVAX covid19 results end Sept beginning Oktober. Stock fall from 12$ to 5.30$ adding time.
1month down.
ABIO super lowfloat stock covid19
From Last Q´s
Basic and diluted
1,793,900
Marketcap only 33.7M
your me it is a buy in and hold. with this thiny float
only need some groups that buying in and hold. And we have a very tight float.
some news and this stock will run
we build a bigger falling wedge
presentation from august:
company augs. pres
Atrial Fibrillation –A Significant Market Opportunity•AF is the most commonsustained cardiac arrhythmia–Affects ~5.2 million (2015) Americans1–2015 worldwide prevalence of AF was estimated at 33 million2•AF is considered an epidemiccardiovascular disease –Based on the rate of increase in incidence in the U.S. and industrialized countries3•Estimated global atrial fibrillation market4–$7.2B in 2015 growing to $12.5B in 2020•ARCA estimate of Gencaro opportunity –$400M to $900M peak revenue in US; similar in EU5
ABIO super lowfloat stock covid19
From Last Q´s
Basic and diluted
1,793,900
Marketcap only 33.7M
your me it is a buy in and hold. with this thiny float
only need some groups that buying in and hold. And we have a very tight float.
some news and this stock will run
we build a bigger falling wedge
presentation from august:
company augs. pres
Atrial Fibrillation –A Significant Market Opportunity•AF is the most commonsustained cardiac arrhythmia–Affects ~5.2 million (2015) Americans1–2015 worldwide prevalence of AF was estimated at 33 million2•AF is considered an epidemiccardiovascular disease –Based on the rate of increase in incidence in the U.S. and industrialized countries3•Estimated global atrial fibrillation market4–$7.2B in 2015 growing to $12.5B in 2020•ARCA estimate of Gencaro opportunity –$400M to $900M peak revenue in US; similar in EU5
ABIO super lowfloat stock covid19
From Last Q´s
Basic and diluted
1,793,900
Marketcap only 33.7M
your me it is a buy in and hold. with this thiny float
only need some groups that buying in and hold. And we have a very tight float.
some news and this stock will run
we build a bigger falling wedge
presentation from august:
company augs. pres
Atrial Fibrillation –A Significant Market Opportunity•AF is the most commonsustained cardiac arrhythmia–Affects ~5.2 million (2015) Americans1–2015 worldwide prevalence of AF was estimated at 33 million2•AF is considered an epidemiccardiovascular disease –Based on the rate of increase in incidence in the U.S. and industrialized countries3•Estimated global atrial fibrillation market4–$7.2B in 2015 growing to $12.5B in 2020•ARCA estimate of Gencaro opportunity –$400M to $900M peak revenue in US; similar in EU5
DVAX a bough some on the earning dip under 10$ easy play
Will hold ETON up so far over 70%
NVAX B Riley raises 2020 year earnings to 26.8$EPS
With a PE of 15
NVAX should see 400$
AQST is, still a buy at this level
TTOO volume alerd breakout above 2$ on very good Q's
FDA decision still on play of emergency use of covid19 sepsis test
TTOO volume alerd breakout above 2$ on very good Q's
FDA decision still on play of emergency use of covid19 sepsis test
TTOO volume alerd breakout above 2$ on very good Q's
FDA decision still on play of emergency use of covid19 sepsis test
SPPI some DD must read
if we get approval for Oct pdufa.
Here you can see the competitor with drug on the market. 1Q earnings from this drug.
If we get 1/3 of the market that amgen had.
Than we have income of 1B$ per year
And only from one drug. We have a good pipline. From 3.5$ I think easy 5 to 10bagger if we get approval and cohort3 will have good data
from last Qs they have 40. 6M net loss and cash on hand around 177.8M
??So we have cash for about 1 year.
Still safe for top line date of cohort3 in the second half.
And pdufa data in Oct. Market size 3B US
SPPI some DD must read
if we get approval for Oct pdufa.
Here you can see the competitor with drug on the market. 1Q earnings from this drug.
If we get 1/3 of the market that amgen had.
Than we have income of 1B$ per year
And only from one drug. We have a good pipline. From 3.5$ I think easy 5 to 10bagger if we get approval and cohort3 will have good data
from last Qs they have 40. 6M net loss and cash on hand around 177.8M
??So we have cash for about 1 year.
Still safe for top line date of cohort3 in the second half.
And pdufa data in Oct. Market size 3B US
SPPI some DD must read
if we get approval for Oct pdufa.
Here you can see the competitor with drug on the market. 1Q earnings from this drug.
If we get 1/3 of the market that amgen had.
Than we have income of 1B$ per year
And only from one drug. We have a good pipline. From 3.5$ I think easy 5 to 10bagger if we get approval and cohort3 will have good data
from last Qs they have 40. 6M net loss and cash on hand around 177.8M
??So we have cash for about 1 year.
Still safe for top line date of cohort3 in the second half.
And pdufa data in Oct. Market size 3B US
SPPI is a good one pdufa in october and the drug have a market of 4B$
Abio this low floater will have their big run like other covid19 plays chart is very similary.
Marketcap only 24M
Float around 1.18M
2offerings was done
9.5M at 9$
And
6.1M also at 9$
March 31 cash was 6.7M
Net loss in 1Q was 1.3M
All in all cash around
22.5M
Q4 phase3 will start
Q3 letter to fda on covid19 drug
AYRO electrical cars chart breakout today. Low floater next news will push this near or in double digits Land. MK 100M is cheap to other electrical car producers
AYRO is a buy at this level easy play
TTOO emergency news from FDA should out any time. 1.94 key breakout point. Skyrock if news will be good
TTOO emergency news from FDA should out any time. 1.94 key breakout point. Skyrock if news will be good
ABIO at this level is a buying more and hold could see 20$ soon
Marketcap is at 20M
35$ and we have a 100M marketcap this will be Okey for the pipline and the upcoming catalysts
ABIO at this level is a buying more and hold could see 20$ soon
Marketcap is at 20M
35$ and we have a 100M marketcap this will be Okey for the pipline and the upcoming catalysts
ABIO breaking out time to get some covid19 low float play. With low marketcap and some catalyst Q3
ABIO Chartbreakout today. Covid play on the beginning. More Infos later
TNXP 84M marketcap next covid19 stock that will go over 1$ low floater
ONTX 2 resistance at 1.10 and 2.20$
ONTX ph3 play breaking out resistance 1.00 than 2.20
Gona ne time yes after consolidation new moving
ONTX breaking out volume comes in ph3 data in 2.half on a medics meeting they said in last Qs
No brainer easy 1$++
ONTX breaking out volume comes in ph3 data in 2.half on a medics meeting they said in last Qs
No brainer easy 1$++
ONTX breaking out volume comes in ph3 data in 2.half on a medics meeting they said in last Qs
No brainer easy 1$++
TTOO time to get some, gap is closed and FDA decision about emergency use this month
yeah men i still holding. biggest volume this year
Also checkout ETON is setting up pdufa play with 3 catalystes
must read
investors presentation